Long-term Disease-Free Survival Achieved by Anti-Angiogenic Therapy Plus Surgery in a Hepatocellular Carcinoma Patient with Extensive Liver Involvement and Lung Metastases.

Yu-Yun Shao,Ming-Chih Ho,Ann-Lii Cheng,Chih-Hung Hsu

DOI: https://doi.org/10.1016/j.jfma.2012.07.036

IF: 3.871

2014-01-01

Journal of the Formosan Medical Association

Abstract:Sorafenib is the current standard treatment for patients with metastatic or advanced hepatocellular carcinoma (HCC) that cannot be treated by loco-regional therapy. However, its objective response rate is only 2e3% and the median time-to-progression is around 2.8 months in the Asian population. Other anti-angiogenic agents, such as bevacizumab, have been reported to have similar efficacy. The long-term disease-free or cure of advanced HCC by anti-angiogenic therapy alone is extremely rare. A 24-year-oldwomanwith no history of chronic hepatitis B or C virus infection was diagnosed with HCC in June 2005 by liver tumor biopsy. Computed tomography scans revealed multiple large intra-hepatic tumors extending into the subhepatic area (Fig. 1A) and bilateral lung metastasis